Last updated: April 27, 2026
What supplier categories do drive Lynparza (olaparib) supply chains?
Lynparza is an oral PARP inhibitor brand. Supply depends on two layers: (1) upstream chemistry for the olaparib API and excipients; and (2) downstream packaging and finished-dose manufacturing. In practice, “suppliers for Lynparza” means the contract manufacturers and ingredient sources that handle API manufacture, drug product manufacturing, and packaging, plus logistics providers that ship finished goods and APIs under GDP/quality systems.
Which company roles define Lynparza supply?
Lynparza is marketed and managed by AstraZeneca; manufacturing and supply execution are typically handled via a network of contract manufacturing organizations (CMOs), contract development and manufacturing organizations (CDMOs), and specialist excipient/packaging vendors. The categories below are the ones that matter for procurement, risk planning, and patent and regulatory diligence.
API (active pharmaceutical ingredient) supply
- Olaparib API manufacturers (scale-up chemistry, purification, crystallization, polymorph control, solvent handling, and API release testing).
- Raw material suppliers feeding key intermediates used to build the olaparib scaffold (starting materials, reagents, catalysts, solvents).
- Analytical testing labs that perform identity, assay, impurities, residual solvents, and stability sampling under cGMP.
Drug product supply
- Tablet manufacturing sites (granulation, compression, coating, in-process controls, tablet hardness/weight uniformity).
- Film coating and dose uniformity controls (operator-critical steps for finished tablets).
- Finished-dose release testing sites.
Packaging and logistics
- Blister pack / bottle packaging suppliers (cold-form blister foils, PVC/Al or Al/Al components, cartons, labels, tamper evidence where applicable).
- Serialisation and track-and-trace compliance components (where required by market).
- GDP logistics providers that handle temperature-qualified distribution, lane management, and chain-of-custody.
Who supplies Lynparza in the market?
What are the documented manufacturer and holder entities behind Lynparza?
AstraZeneca holds commercialization responsibility for Lynparza across major markets. Manufacturing and supply chain execution are performed by labeled manufacturing sites associated with regulatory filings (marketing authorization dossiers) and cGMP inspection records.
However, supplier identity for “who provides Lynparza” is not consistently published in a single public list by brand name, and the exact set of sites depends on:
- country (EU, US, UK, Japan, etc.),
- strength (10 mg, 50 mg; and other dosage forms depending on jurisdiction),
- packaging format (bottles vs blisters),
- manufacturing changes over time (site transfers, tech transfers, and batch reassignments).
Because your question asks for “suppliers,” the actionable answer is a supplier map by functional role, not a single supplier name.
Which suppliers matter most for continuity risk?
From a continuity and cost standpoint, the most material supplier nodes for an oral PARP inhibitor like olaparib are:
- Olaparib API manufacturing sites (single-site dependency is the key risk driver).
- Key intermediate and chiral starting material sources (where supply constraints cascade).
- Tablet compression/coating CMOs handling the dosage form and packaging line integration.
What suppliers are typical for olaparib oral tablet supply networks?
In global practice, olaparib tablet supply networks use:
- a small number of API sites (often 1 to 3 globally),
- a small number of tablet and coating sites,
- packaging suppliers capable of serialization and region-specific artwork/labeling.
But without a country- and dosage-strength-specific regulatory dossier extraction, listing named suppliers would be incomplete and could misstate current manufacturing assignments.
How to interpret “suppliers for Lynparza” for procurement and due diligence
For procurement and investment diligence, “suppliers” should be interpreted as:
- GMP manufacturing sites for API and finished tablets (the entities that build and release),
- contract packaging partners (the entities that provide pack components and labeling integration),
- specialist component vendors (coating materials, desiccants, blister foils, bottle materials, and ink/label systems).
Lynparza supplier map template (what you should lock in per market and strength)
| Supply node |
Supplier type |
What to verify |
Why it matters |
| Olaparib API |
API manufacturer/CDMO |
Site address, batch release testing, polymorph control, residual solvents |
Highest risk for supply interruption |
| API starting materials & intermediates |
Raw material suppliers |
Specification ranges, impurity profile control, change-of-source governance |
Impurity drift drives batch failures |
| Tablet manufacturing |
Drug product CMO |
Compression/coating process controls, in-process testing strategy |
Weight uniformity and dissolution controls |
| Packaging |
Packaging CMO/vendor |
Blister or bottle components, serialization capability, labeling approvals |
Market compliance and shelf readiness |
| Distribution |
GDP logistics |
Temperature controls, lane ownership, chain-of-custody |
Prevents product loss and recalls |
Key Takeaways
- “Suppliers for Lynparza” is best treated as a network across API manufacture, drug product manufacturing, and packaging rather than one vendor.
- The highest continuity risk sits in olaparib API production and the key intermediate raw material sources that feed olaparib synthesis.
- For any named supplier list, you need market and strength alignment because manufacturing assignments change by dossier and time.
FAQs
1) Who is the main company responsible for Lynparza supply?
AstraZeneca is the commercial and regulatory responsibility holder for Lynparza, while manufacturing and packaging are executed through cGMP suppliers and CDMOs.
2) What supplier category is the most critical for Lynparza continuity?
API manufacturing for olaparib is the most critical node because downstream tablet and packaging lines cannot operate without released API.
3) Are Lynparza suppliers the same for all countries?
No. Manufacturing site assignments and packaging configurations differ by market and regulatory dossier.
4) What are the most common bottlenecks in olaparib supply chains?
Key intermediate availability, API crystallization/polymorph control, and tablet coating and packaging line integration.
5) How should a buyer structure supplier due diligence for Lynparza?
By node: confirm API release capability and quality systems, then drug product cGMP controls, then packaging serialization and labeling compliance, followed by GDP distribution.
References
[1] AstraZeneca. Lynparza (olaparib) product and regulatory information. AstraZeneca. https://www.astrazeneca.com/ (accessed 2026-04-28).
